Control of Microbe Growth via Novel Regulatory Events in the TORC Pathway

Technology #ua15-122

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Andrew Capaldi
Assistant Professor, Molecular and Cellular Biology
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Background: Human diseases caused by eukaryotes include fungal infections and parasitic diseases. Parasitic diseases include not only those caused by helminths (parasitic worms), but also protozoans such as Plasmodium (a group of protozoans responsible for causing malaria), Leishmania (a group of protozoans responsible for causing leishmaniasis), and giardia.

 

Invention: The present invention relates to systems, methods, and compositions for treating or preventing diseases associated with eukaryotic organisms, more particularly to methods and compositions for directly or indirectly triggering and/or permitting, or inhibiting Raptor/Kog1 aggregation in specific eukaryotes.  This technology is a proposed class of novel drugs for the treatment of diseases caused by eukaryotic organisms, and a method of screening for such drugs. These antifungal and antiparasitic drugs will rely on a newly discovered cell signaling pathway that is present in many eukaryotes that cause infection in humans, but is not present in human cells. It is expected that these drugs could be used alone or in conjunction with other drugs to fight such infections.

 

Applications: This proposed class of drugs can be used to treat infections caused by eukaryotes, including but fungal infections and infections caused by parasites such as various parasitic worms. Additionally, these drugs might have efficacy in treating other infections caused by other eukaryotes, such as malaria, visceral leishmaniasis, giardiasis, and amebiasis.

 

Advantages: Because the cell signaling pathway that is the functional basis for these drugs is not present in human cells, it is expected that these drugs will potentially have a low side effect profile and will be safe to use in conjunction with existing treatments.

 

Lead Inventors: Andrew Capaldi PhD

 

Licensing Manager: Paul Eynott PhD MBA